United States Biotechnology & Medical Research

Lyell Immunopharma Inc (LYEL)

Track

Over the past 90 days, Lyell Immunopharma Inc. recorded seven insider transactions, all of which were sales, resulting in a net negative value of approximately $11,715. These transactions involved several executives, including the CEO and CMO, and occurred following the company's May 2026 earnings report. The stock has declined 37.1% over the last quarter.
Ticker: LYEL Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Lyell Immunopharma Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Sale 17 Jul 2026
Value US$1,676,034.56 | Price 168.74 | Shares 1,057 (+10.7%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-20 2026-07-17 S Sale
Innovative Cellular Therapeutics Holdings Ltd
Large shareholder
1,057 +10.7%
168.74
US$1,676,035 		1,057 +10.7% 168.74 US$1,676,035
2026-07-17 2026-07-16 S Sale
Innovative Cellular Therapeutics Holdings Ltd
Large shareholder
56,622 +32.2%
120.07
US$2,443,970 		56,622 +32.2% 120.07 US$2,443,970
2026-06-11 2026-06-10 PlS Planned sale
3.1
Shook David

Chief Medical Officer

Officer
42,513 +15.9%
212.53
US$1,270,703 		42,513 +15.9% 212.53 US$1,270,703
2026-06-15 2026-05-11 S Sale
2.2
Seely Lynn

President and CEO

Executive Director
388 -0.5%
18.91
US$7,337 		388 -0.5% 18.91 US$7,337
2026-06-15 2026-05-11 PlS Planned sale
2.4
Lee Gary K.

Chief Scientific Officer

Officer
130 -0.7%
18.92
US$2,460 		130 -0.7% 18.92 US$2,460
2026-06-15 2026-05-11 PlS Planned sale
2.5
Hill Stephen J.

Chief Operating Officer

Officer
89 -0.5%
18.92
US$1,684 		89 -0.5% 18.92 US$1,684
2026-06-15 2026-05-11 S Sale
3.8
Bulis Veronica Sanchez

VP, Corporate Controller

Officer
217 -1.4%
18.91
US$4,103 		217 -1.4% 18.91 US$4,103
2026-03-09 2026-03-06 B Purchase
ARCH Venture Partners IX, LLC
Large shareholder
488,090 +52.0%
25.61
US$12,499,985 		488,090 +52.0% 25.61 US$12,499,985
2026-03-09 2026-03-06 B Purchase
ARCH Venture Fund XIII, L.P.
Large shareholder
488,090 +52.0%
25.61
US$12,499,985 		488,090 +52.0% 25.61 US$12,499,985
2026-02-12 2026-02-11 S Sale
2.5
Hill Stephen J.

Chief Operating Officer

Officer
1,236 -6.5%
23.39
US$28,910 		1,236 -6.5% 23.39 US$28,910
2026-02-12 2026-02-11 S Sale
2.2
Seely Lynn

President and CEO

Executive Director
7,455 -9.1%
23.39
US$174,372 		7,455 -9.1% 23.39 US$174,372
2026-02-12 2026-02-11 S Sale
2.4
Lee Gary K.

Chief Scientific Officer

Officer
1,671 -9.0%
23.39
US$39,085 		1,671 -9.0% 23.39 US$39,085
2026-02-11 2026-02-10 S Sale
2.4
Lee Gary K.

Chief Scientific Officer

Officer
147 -0.8%
23.12
US$3,399 		147 -0.8% 23.12 US$3,399
2026-02-11 2026-02-10 S Sale
2.2
Seely Lynn

President and CEO

Executive Director
438 -0.5%
23.12
US$10,127 		438 -0.5% 23.12 US$10,127
2026-02-11 2026-02-10 S Sale
2.5
Hill Stephen J.

Chief Operating Officer

Officer
109 -0.6%
23.12
US$2,520 		109 -0.6% 23.12 US$2,520
2026-02-11 2026-02-10 S Sale
3.8
Bulis Veronica Sanchez

VP, Corporate Controller

Officer
254 -1.6%
23.12
US$5,872 		254 -1.6% 23.12 US$5,872
2026-01-06 2025-12-30 S Sale
3.8
Bulis Veronica Sanchez

VP, Corporate Controller

Officer
936 -11.6%
32.32
US$30,252 		936 -11.6% 32.32 US$30,252
2026-01-06 2025-12-24 S Sale
3.8
Bulis Veronica Sanchez

VP, Corporate Controller

Officer
1,136 -12.3%
38.67
US$43,929 		1,136 -12.3% 38.67 US$43,929
2025-11-12 2025-11-10 S Sale
2.5
Hill Stephen J.

Chief Operating Officer

Officer
95 -0.6%
16.12
US$1,531 		95 -0.6% 16.12 US$1,531
2025-11-12 2025-11-10 S Sale
3.8
Bulis Veronica Sanchez

VP, Corporate Controller

Officer
239 -2.5%
16.10
US$3,848 		239 -2.5% 16.10 US$3,848
2025-11-12 2025-11-10 S Sale
2.2
Seely Lynn

President and CEO

Executive Director
412 -0.6%
16.11
US$6,637 		412 -0.6% 16.11 US$6,637
2025-11-12 2025-11-10 S Sale
2.4
Lee Gary K.

Chief Scientific Officer

Officer
138 -0.9%
16.16
US$2,230 		138 -0.9% 16.16 US$2,230
2025-08-22 2025-08-21 S Sale
2.2
Seely Lynn

President and CEO

Executive Director
7,257 -9.7%
10.54
US$76,518 		7,257 -9.7% 10.54 US$76,518
2025-08-22 2025-08-21 S Sale
2.4
Lee Gary K.

Chief Scientific Officer

Officer
1,453 -8.6%
10.54
US$15,320 		1,453 -8.6% 10.54 US$15,320
2025-08-22 2025-08-21 S Sale
2.5
Hill Stephen J.

Chief Operating Officer

Officer
1,004 -6.0%
10.54
US$10,586 		1,004 -6.0% 10.54 US$10,586
2025-08-22 2025-08-21 S Sale
1.5
Newton Charles W.

Chief Financial Officer

Officer
1,453 -8.7%
10.54
US$15,320 		1,453 -8.7% 10.54 US$15,320
2025-08-13 2025-08-12 S Sale
2.2
Seely Lynn

President and CEO

Executive Director
406 -1.2%
10.34
US$4,197 		406 -1.2% 10.34 US$4,197
2025-08-13 2025-08-12 S Sale
2.5
Hill Stephen J.

Chief Operating Officer

Officer
94 -1.1%
10.34
US$972 		94 -1.1% 10.34 US$972
2025-08-13 2025-08-12 S Sale
2.4
Lee Gary K.

Chief Scientific Officer

Officer
136 -1.5%
10.34
US$1,406 		136 -1.5% 10.34 US$1,406
2025-08-13 2025-08-12 S Sale
1.5
Newton Charles W.

Chief Financial Officer

Officer
136 -1.5%
10.34
US$1,406 		136 -1.5% 10.34 US$1,406
2025-08-13 2025-08-11 S Sale
2.2
Seely Lynn

President and CEO

Executive Director
391 -1.1%
10.53
US$4,116 		391 -1.1% 10.53 US$4,116
2025-08-13 2025-08-11 PlS Planned sale
2.5
Hill Stephen J.

Chief Operating Officer

Officer
91 -1.0%
10.53
US$958 		91 -1.0% 10.53 US$958
2025-08-13 2025-08-11 PlS Planned sale
2.4
Lee Gary K.

Chief Scientific Officer

Officer
131 -1.4%
10.53
US$1,379 		131 -1.4% 10.53 US$1,379
2025-08-13 2025-08-11 PlS Planned sale
1.5
Newton Charles W.

Chief Financial Officer

Officer
131 -1.5%
10.53
US$1,379 		131 -1.5% 10.53 US$1,379
2025-04-02 2025-03-31 B Purchase
1.4
BRAWLEY OTIS W
Non-Executive Director
35,640 +inf%
0.56
US$19,958 		35,640 +inf% 0.56 US$19,958
2025-03-25 2025-03-21 B Purchase
0.6
Ramachandra Sumant
Non-Executive Director
200,000 +inf%
0.58
US$115,220 		200,000 +inf% 0.58 US$115,220
2025-03-18 2025-03-17 B Purchase
1.5
Newton Charles W.

Chief Financial Officer

Officer
200,000 +inf%
0.56
US$111,620 		200,000 +inf% 0.56 US$111,620
2025-03-18 2025-03-14 B Purchase
3.2
Klausner Richard
Non-Executive Director
158,000 +23.1%
0.60
US$94,942 		158,000 +23.1% 0.60 US$94,942
2025-03-18 2025-03-14 B Purchase
2.2
Seely Lynn

President and CEO

Executive Director
175,000 +32.6%
0.61
US$106,190 		175,000 +32.6% 0.61 US$106,190
2023-08-17 2023-08-15 S Sale
3.2
Klausner Richard
Non-Executive Director
58,020 -5.9%
2.28
US$132,286 		58,020 -5.9% 2.28 US$132,286
2023-08-15 2023-08-15 PrS Proposed sale
3.2
Klausner Richard

Director

Non-Executive Director
4,485
2.29
US$10,271 		4,485 2.29 US$10,271
2023-08-15 2023-08-15 PrS Proposed sale
3.2
Klausner Richard

Director

Non-Executive Director
4,485
2.29
US$10,271 		4,485 2.29 US$10,271
2023-08-15 2023-08-15 PrS Proposed sale
3.2
Klausner Richard

Director

Non-Executive Director
44,565
2.29
US$102,054 		44,565 2.29 US$102,054
2023-08-15 2023-08-15 PrS Proposed sale
3.2
Klausner Richard

Director

Non-Executive Director
4,485
2.29
US$10,271 		4,485 2.29 US$10,271
2023-07-17 2023-07-13 PrS Proposed sale
3.2
Klausner Richard

Officer; Director

Executive Director
14,500
2.90
US$42,050 		14,500 2.90 US$42,050
2023-07-17 2023-07-13 PrS Proposed sale
3.2
Klausner Richard

Officer; Director

Executive Director
3,300
2.90
US$9,570 		3,300 2.90 US$9,570
2023-07-17 2023-07-13 PrS Proposed sale
3.2
Klausner Richard

Officer; Director

Executive Director
3,300
2.90
US$9,570 		3,300 2.90 US$9,570
2023-07-17 2023-07-13 PrS Proposed sale
3.2
Klausner Richard

Officer; Director

Executive Director
3,300
2.90
US$9,570 		3,300 2.90 US$9,570
2022-09-27 2022-09-23 S Sale
3.2
Klausner Richard
Non-Executive Director
11,100 -1.1%
6.40
US$71,041 		11,100 -1.1% 6.40 US$71,041
2021-06-23 2021-06-21 B Purchase
0.6
FRIEDMAN CATHY
Non-Executive Director
17,648 +inf%
17.00
US$300,016 		17,648 +inf% 17.00 US$300,016
Explore more

More insider trading research around Lyell Immunopharma Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America